Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
s-Amlodipine + chlorthalidone is a fixed-dose combination of two antihypertensive agents used primarily for the treatment of high blood pressure. s-Amlodipine is the S-enantiomer of amlodipine, a long-acting calcium channel blocker that inhibits L-type calcium channel (Cav1.2) in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced peripheral vascular resistance. Chlorthalidone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption by blocking the Sodium-chloride symporter (SLC12A3) in the distal convoluted tubule of the kidney, resulting in increased excretion of sodium and water, decreased plasma volume, and lowered blood pressure. The combination targets both vascular tone (via s-amlodipine) and fluid balance (via chlorthalidone), providing additive antihypertensive effects[3][4][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on s-Amlodipine + Chlorthalidone.